Implementing AHRQ Effective Health Care Reviews

Helping Clinicians Make Better Treatment Choices

Treatment of Knee Osteoarthritis

Practice Pointers by Kenneth W. Lin, MD, MPH

Georgetown University Medical Center, Washington, District of Columbia

Key Clinical Issue

What are the clinical effectiveness and harms of cell-based therapies, oral glucosamine and/or chondroitin, physical treatment interventions, weight loss, and home-based and self-management therapies for knee osteoarthritis (OA)?

Evidence-Based Answer

For short-term (four to 12 weeks) pain relief and/ or improvement of function, beneficial interventions include transcutaneous electrical nerve stimulation (TENS), tai chi, and home-based and self-management programs. (Strength of Recommendation [SOR]: B, based on inconsistent or limited-quality patient-oriented evidence.) Platelet-rich plasma injections and home-based and self-management programs reduce pain in the medium term (12 to 26 weeks). (SOR: B, based on inconsistent or limited-quality patientoriented evidence.) Glucosamine and chondroitin supplements have medium-term but not longterm benefits. (SOR: B, based on inconsistent or limited-quality patient-oriented evidence.) Shoe inserts are ineffective. (SOR: B, based on inconsistent or limited-quality patient-oriented evidence.) For long-term (more than 26 weeks) outcomes, beneficial interventions include weight loss, agility training, combined exercise programs, and manual therapy (i.e., massage, self-massage, and acupressure). (SOR: B, based on inconsistent or limited-quality patient-oriented evidence.) There is insufficient evidence to determine whether treatment outcomes or adverse events vary in different populations.¹

Practice Pointers

Symptomatic OA of the knee affects an estimated 10% of men and 13% of women 60 years or older in the United States.² Knee OA is characterized by destruction of articular and subchondral bone cartilage and osteophyte formation, and causes pain with weight-bearing, limitation of movement, and reduction in function, including the ability to complete activities of daily living.^{1,3} Goals of treatment include pain relief and improvement in function and health-related quality of life.

This Agency for Healthcare Research and Quality (AHRQ) review included 107 studies regarding the effectiveness of cell-based therapies, oral glucosamine and/or chondroitin, physical treatment interventions, weight loss, or home-based and self-management therapies in patients with knee OA. Based on low strength

The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to produce evidence to improve health care and to make sure the evidence is understood and used. A key clinical question based on the AHRQ Effective Health Care Program systematic review of the literature is presented, followed by an evidence-based answer based upon the review. AHRQ's review is accompanied by an interpretation by an *AFP* author that will help guide clinicians in making treatment decisions. For the full review, go to https://effectivehealthcare.ahrq.gov/topics/osteoarthritis-knee-update/research-2017.

This series is coordinated by Kenny Lin, MD, MPH, Deputy Editor.

A collection of Implementing AHRQ Effective Health Care Reviews published in *AFP* is available at https://www.aafp.org/afp/ahrq.

This clinical content conforms to AAFP criteria for continuing medical education (CME). See CME Quiz on page 569.

Author disclosure: No relevant financial affiliations.

CLINICAL BOTTOM LINE

		Number of		
Intervention/ follow-up	Comparison	studies (pain/ function)	Findings	Strength of evidence
Platelet-rich pla	sma			
Medium term	Placebo	4/—	Reduced pain	•00
Glucosamine wi	th or without chondre	oitin		
Glucosamine plu	us chondroitin			
Medium term	Analgesic or placebo	3/3	Reduced pain, improved function*	
Long term	Placebo	3/3	No benefit on pain or function†	
Glucosamine				
Long term	Placebo	3/3	No benefit on pain or function	$\bullet \bullet \bigcirc$
Chondroitin				
Medium term	Placebo	2/—	Reduced pain	•00
Long term	Placebo	3/2	No benefit on pain or function	••0/•00
Aerobic exercise	2			
Long term	Inactive control	-/ 3	No benefit on function	•00
Strongth and ro	sistance training			
Short term	Inactive control	5/5	No benefit on pain or	•00
311011111111111111111111111111111111111	mactive control	3/3	function†	
Medium term	Inactive control	-/3	No benefit on function†	•00
Agility training				
Short term	Inactive control	3/3	Reduced pain, no benefit on function‡	•00
Medium term	Active and inactive controls	3/3	No benefit on pain or function	•00
Long term	Active and inactive controls	3/2	Reduced pain and improved function	•00
General/combir	ned exercise			
Medium term	Inactive control	2/2	Reduced pain and improved function	•00
Long term	Inactive control	3/—	Reduced pain	•00
Tai chi				
Short term	Active and inactive controls	3/3	Reduced pain and improved function	•00
Medium term	Active and inactive controls	2/2	Reduced pain and improved function	•00
Manual therapy				
Short term	Treatment as usual or rehab alone	3/4	No benefit on pain or function†	•00
Long term	Treatment as usual or rehab alone	2/—	Reduced pain	•00
Balneotherapy				
Medium term	Treatment as usual or active control	2/2	No benefit on pain, improved function	•00

CLINICAL BOTTOM LINE (continued)

Treatment of Knee Osteoarthritis

Intervention/ follow-up	Comparison	Number of studies (pain/ function)	Findings	Strength of evidence
Pulsed electrom	agnetic field			
Short term	Sham control	3/—	No benefit on pain†	•00
Transcutaneous	electrical nerve stimu	ulation		
Short term	Sham control	4/3	Reduced pain, no benefit on function§	••0/•00
Medium term	Sham control	2/2	No benefit on pain or function	\bullet
Whole-body vib	ration			
Short term	Strength training alone	3/—	No benefit on pain	•00
Medium term	Strength training alone	4/4	No benefit on pain, improved function†§	•00
Orthoses				
Shoe inserts				
Short term	Neutral or no insoles	4/3	No benefit on pain or function†	
Medium term	Neutral or no insoles	3/4	No benefit on pain or function†	•00
Weight loss				
Medium term	No diet/exercise or no comparator	6/6	Reduced pain and improved function	••0/•00
Long term	No diet/exercise or no comparator	4/—	Reduced pain	• • • •
Home-based an	d self-management p	rograms		
Short term	Usual care	2/—	Reduced pain	•00
Medium term	Usual care	3/4	Reduced pain and improved function	•00
Strength of evid	ence scale			
•	h confidence that the the the confidence in the		ts the true effect. Further research ect.	is very unlikely
			nce reflects the true effect. Furthe and may change the estimate.	r research may

- ○○ Low: Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.
- ○○○ **Insufficient**: Evidence either is unavailable or does not permit a conclusion.
- *—Beneficial effect vs. analgesic or placebo.
- †-Pooled analysis.
- ‡—Compared with placebo but not strength training.
- §—Did not meet a minimum clinically important difference.
- ||—Randomized controlled trials and single-arm trials.

Adapted from the Agency for Healthcare Research and Quality, Effective Health Care Program. Treatment of osteoarthritis of the knee: an update review. Rockville, Md.: Agency for Healthcare Research and Quality; May 2017. https://effec tivehealthcare.ahrq.gov/sites/default/files/pdf/osteoarthritis-knee-update_research-2017.pdf. Accessed July 19, 2018.

of evidence from four randomized controlled trials (RCTs), platelet-rich plasma injections reduce pain and improve quality of life compared with placebo for up to 26 weeks. Based on

moderate strength of evidence from three RCTs, the combination of glucosamine and chondroitin improves medium-term outcomes but has no benefits beyond 26 weeks. Compared with sham

controls, TENS reduces pain in the short term but not function and does not improve function or pain after 12 weeks.

Regarding exercise, 10 studies found no statistically significant benefit of strength and resistance training on pain or function for up to 26 weeks. Similarly, three RCTs of aerobic exercise alone found no long-term benefits on function. However, three RCTs of agility training showed modest benefits on long-term pain and function, and programs that combine strength and aerobic exercise interventions reduce pain and improve function in the medium term and reduce pain in the long term, based on four RCTs. Home-based exercise and self-management programs that include strength, agility, and pain-coping skills have beneficial effects in the short and medium term. Tai chi also appears to improve short- and medium-term outcomes, based on low strength of evidence from three RCTs. There was insufficient evidence to assess the effects of yoga.

Weight loss (achieved with diet and/or exercise) reduces pain and improves function in the medium term and reduces pain in the long term, based on low to moderate strength of evidence.

Shoe inserts had no effect on pain or function in eight RCTs. There was insufficient evidence to determine the effectiveness of knee braces, custom shoes, or cane use.

Adverse events were reported in 57 studies. Of therapies found to be at least partially effective, platelet-rich plasma injections were associated with knee pain and stiffness in 44% of patients who received two injections in one RCT. There were no differences in adverse events between glucosamine and/or chondroitin and placebo or active controls. There was no difference in worsening of knee symptoms following TENS between intervention and sham control groups. Persons on weight loss diets reported more nonserious gastrointestinal symptoms (e.g., constipation). Serious adverse events were rarely reported and not limited to active treatment groups.

The AHRQ review findings were mostly consistent with 2013 practice guidelines from the American Academy of Orthopaedic Surgeons (AAOS), which recommend self-management programs and low-impact aerobic exercise for persons with symptomatic knee OA and weight loss for persons with a body mass index of 25 kg per m² or greater. The AAOS recommends against the use

of glucosamine, chondroitin, and lateral wedge insoles. The recommendation against the use of glucosamine and chondroitin is based on the absence of evidence that these supplements slow cartilage loss or have long-term benefits and the lack of regulation of these therapies by the U.S. Food and Drug Administration.⁴

Nonsurgical interventions for knee OA that were not evaluated in the AHRQ review include corticosteroid and hyaluronic acid injections, acupuncture, and oral and topical medications. A Cochrane review found that most RCTs that suggest short-term benefits of intra-articular corticosteroids are limited by methodological issues, primarily unblinding.⁵ Another systematic review and meta-analysis found that double-blinded, sham-controlled trials of hyaluronic acid injections do not show a clinically significant benefit.⁶ The AAOS guideline recommends against acupuncture for knee OA because the few studies that reported positive outcomes were statistically, but not clinically, significant.⁴

Editor's Note: American Family Physician SOR ratings are different from the AHRQ Strength of Evidence (SOE) ratings.

Address correspondence to Kenneth W. Lin, MD, MPH, at kenneth.lin@georgetown.edu. Reprints are not available from the author.

References

- Agency for Healthcare Research and Quality, Effective Healthcare Program. Treatment of osteoarthritis of the knee: an update review. Rockville, Md.: Agency for Healthcare Research and Quality; May 2017. https://effectivehealthcare.ahrq.gov/topics/osteoarthritis-knee-update/research-2017. Accessed July 19, 2018.
- Zhang Y, Jordan JM. Epidemiology of osteoarthritis [published correction appears in *Clin Geriatr Med.* 2013;29(2): ix]. *Clin Geriatr Med.* 2010;26(3):355-369.
- 3. Ringdahl E, Pandit S. Treatment of knee osteoarthritis. *Am Fam Physician*. 2011;83(11):1287-1292.
- 4. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee: evidence-based guideline 2nd edition. May 2013. https://www.aaos.org/research/guidelines/TreatmentofOsteoarthritisoftheKnee Guideline.pdf. Accessed June 22, 2018.
- Jüni P, Hari R, Rutjes AW, et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev. 2015;(10):CD005328.
- 6. Jevsevar D, Donnelly P, Brown GA, Cummins DS. Viscosupplementation for osteoarthritis of the knee: a systematic review of the evidence. *J Bone Joint Surg Am.* 2015; 97(24):2047-2060. ■